BELLA (NCT06906341) has completed enrollment testing triplet strategies such as adding bevacizumab and expanding evaluation ...
On April 11, Corcept Therapeutics Inc. (NASDAQ:CORT) released the overall survival results from its Phase 3 ROSELLA study ...
Credit: Corcept Therapeutics. FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens. The ROSELLA study ...
In this study, researchers aimed to examine survival outcomes with elraglusib plus chemotherapy compared to chemotherapy alone in untreated mPDAC.
Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy ...
These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...
Alternating neoadjuvant gemcitabine-nab-paclitaxel (GnP) and nal-irinotecan, 5-fluorouracil and folinic acid (nal-IRI) regimens in resectable (R) and borderline resectable (BR) pancreatic cancer (PC): ...
Combining relacorilant with nab-paclitaxel extended median overall survival to 16.0 months versus 11.9 months and reduced mortality risk by 35% versus nab-paclitaxel alone. Landmark survival favored ...
Disease control is the primary clinical objective, and Lifyorli plus weekly nab-paclitaxel prolongs time on therapy without progression while generally preserving day-to-day function through tolerable ...
Results from ROSELLA showed a 35% reduction in the risk of death in patients treated with relacorilant plus nab-paclitaxel compared with nab-paclitaxel alone. Treatment with relacorilant, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results